Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Bridgepoint in conjunction with its investment in Vitamin Well
Mandate

Vinge advises Bridgepoint in conjunction with its investment in Vitamin Well

November 29, 2016

Vinge has advised Bridgepoint Development Capital in conjunction with its investment in Vitamin Well AB. Vitamin Well AB is a leading Nordic company within functional drinks, which develops, markets and sells high-quality drinks under the well-known trademarks Vitamin Well, Vitamin Well Free, NOBE aloe vera, NOCCO and the sports drink Vitamin Well+.

Following its formation in 2006, Vitamin Well AB has had the vision of being the best and the tastiest functional drinks manufacturer, adapted for various different target groups and situations. Vitamin Well has its headquarters in Stockholm, employs 84 persons and its drinks are sold in 28 countries. The transaction is conditional upon approval from the Swedish Competition Authority.

Vinge’s team consists of partner Daniel Rosvall together with, among others, associates Samra Baytar and Ilze Lukins (M&A), Tomas Forsgren (intellectual property), Lisa Sennerby (employment), Kristoffer Larson (real estate), Albert Wållgren and Karl Klackenberg (banking & finance) and counsel Johan Cederblad (regulatory issues). Grant McKelvey and Marita Ljunggren are advising on competition law notification issues.

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025